Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.28 Billion KRW | 50.68% |
| 2022 | -47.21 Billion KRW | -1365.05% |
| 2021 | 3.73 Billion KRW | -88.19% |
| 2020 | 31.6 Billion KRW | 36344.82% |
| 2019 | 86.71 Million KRW | -99.78% |
| 2018 | 40.16 Billion KRW | 972.11% |
| 2017 | -4.6 Billion KRW | -389.92% |
| 2016 | 1.58 Billion KRW | -23.09% |
| 2015 | 2.06 Billion KRW | -72.69% |
| 2014 | 7.56 Billion KRW | -0.15% |
| 2013 | 7.57 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -9.32 Billion KRW | -68.11% |
| 2024 Q1 | -5.54 Billion KRW | 74.52% |
| 2023 FY | -23.28 Billion KRW | 50.68% |
| 2023 Q3 | -273.62 Million KRW | 91.24% |
| 2023 Q1 | 1.87 Billion KRW | 106.72% |
| 2023 Q4 | -21.76 Billion KRW | -7854.0% |
| 2023 Q2 | -3.12 Billion KRW | -266.77% |
| 2022 Q4 | -27.89 Billion KRW | -5678.04% |
| 2022 FY | -47.21 Billion KRW | -1365.05% |
| 2022 Q3 | 500.08 Million KRW | 104.5% |
| 2022 Q2 | -11.11 Billion KRW | -27.61% |
| 2022 Q1 | -8.71 Billion KRW | 57.49% |
| 2021 FY | 3.73 Billion KRW | -88.19% |
| 2021 Q4 | -20.48 Billion KRW | 1.3% |
| 2021 Q2 | 46.82 Billion KRW | 2638.02% |
| 2021 Q1 | -1.84 Billion KRW | -120.54% |
| 2021 Q3 | -20.75 Billion KRW | -144.33% |
| 2020 FY | 31.6 Billion KRW | 36344.82% |
| 2020 Q1 | -9.43 Billion KRW | -187.58% |
| 2020 Q2 | 24.44 Billion KRW | 359.17% |
| 2020 Q3 | 7.6 Billion KRW | -68.88% |
| 2020 Q4 | 8.98 Billion KRW | 18.05% |
| 2019 Q3 | -11.51 Billion KRW | 51.82% |
| 2019 Q1 | 24.72 Billion KRW | 21.14% |
| 2019 FY | 86.71 Million KRW | -99.78% |
| 2019 Q4 | 10.77 Billion KRW | 193.54% |
| 2019 Q2 | -23.89 Billion KRW | -196.64% |
| 2018 Q2 | 18.54 Billion KRW | 1703.11% |
| 2018 FY | 40.16 Billion KRW | 972.11% |
| 2018 Q4 | 20.41 Billion KRW | 10901.18% |
| 2018 Q3 | 185.54 Million KRW | -99.0% |
| 2018 Q1 | 1.02 Billion KRW | 126.22% |
| 2017 FY | -4.6 Billion KRW | -389.92% |
| 2017 Q1 | -182.54 Million KRW | -115.0% |
| 2017 Q2 | 543.52 Million KRW | 397.75% |
| 2017 Q3 | -1.04 Billion KRW | -292.28% |
| 2017 Q4 | -3.92 Billion KRW | -275.25% |
| 2016 FY | 1.58 Billion KRW | -23.09% |
| 2016 Q4 | 1.21 Billion KRW | 197.71% |
| 2016 Q3 | -1.24 Billion KRW | -200.39% |
| 2016 Q2 | -414.69 Million KRW | -120.41% |
| 2016 Q1 | 2.03 Billion KRW | 61.46% |
| 2015 Q3 | -778.19 Million KRW | -205.77% |
| 2015 Q2 | 735.72 Million KRW | -13.41% |
| 2015 Q1 | 849.61 Million KRW | -78.81% |
| 2015 FY | 2.06 Billion KRW | -72.69% |
| 2015 Q4 | 1.25 Billion KRW | 261.72% |
| 2014 Q2 | 807.41 Million KRW | -48.47% |
| 2014 Q1 | 1.56 Billion KRW | -43.49% |
| 2014 Q3 | 1.17 Billion KRW | 46.12% |
| 2014 Q4 | 4 Billion KRW | 239.79% |
| 2014 FY | 7.56 Billion KRW | -0.15% |
| 2013 Q4 | 2.77 Billion KRW | 945.44% |
| 2013 FY | 7.57 Billion KRW | 0.0% |
| 2013 Q2 | 2.41 Billion KRW | 13.74% |
| 2013 Q3 | 265.24 Million KRW | -89.01% |
| 2013 Q1 | 2.12 Billion KRW | 0.0% |
| 2012 Q3 | 563.73 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 87.683% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -140.206% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 598.612% |
| Bioneer Corporation | -10.58 Billion KRW | -119.976% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -719.787% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 498.783% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 52.397% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 63.661% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -176.221% |
| Medy-Tox Inc. | 9.75 Billion KRW | 338.736% |
| Peptron, Inc. | -15.92 Billion KRW | -46.27% |
| Genexine, Inc. | -66.87 Billion KRW | 65.175% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -911.612% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 68.402% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -590.704% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 130.423% |
| SillaJen, Inc. | -20.36 Billion KRW | -14.334% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 266.755% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | -21.921% |
| Genomictree Inc. | -8.75 Billion KRW | -165.976% |
| MedPacto, Inc. | -35.32 Billion KRW | 34.072% |
| D&D Pharmatech | 3.93 Billion KRW | 692.02% |
| EASY BIO,Inc. | 15.54 Billion KRW | 249.828% |
| GI Innovation, Inc. | -55.49 Billion KRW | 58.034% |